Pharvaris (PHVS) FCF Payout Ratio Growth (1y) (2021 - 2026)
Pharvaris (PHVS) FCF Payout Ratio Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 68.88% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -31.89% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Pharvaris | 2.29 Bn | 1.92 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.88% |
| Dec 31, 2025 | 4.75% |
| Sep 30, 2025 | -463.38% |
| Jun 30, 2025 | 37.38% |
| Mar 31, 2025 | 59.44% |
| Dec 31, 2024 | 50.96% |
| Sep 30, 2024 | 129.66% |
| Jun 30, 2024 | 122.82% |
| Mar 31, 2024 | -183.57% |
| Dec 31, 2023 | -107.27% |
| Sep 30, 2023 | -1,726.10% |
| Jun 30, 2023 | -711.92% |
| Mar 31, 2023 | 50.80% |
| Dec 31, 2022 | 52.86% |
| Sep 30, 2022 | -57.76% |
| Jun 30, 2022 | -140.87% |
| Mar 31, 2022 | 53.36% |
| Sep 30, 2021 | 113.67% |
| Jun 30, 2021 | 18.10% |
| Mar 31, 2021 | -200.73% |